GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kane Biotech Inc (TSXV:KNE) » Definitions » ROC %

Kane Biotech (TSXV:KNE) ROC % : -99.71% (As of Sep. 2024)


View and export this data going back to 2003. Start your Free Trial

What is Kane Biotech ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Kane Biotech's annualized return on capital (ROC %) for the quarter that ended in Sep. 2024 was -99.71%.

As of today (2025-03-27), Kane Biotech's WACC % is 6.51%. Kane Biotech's ROC % is -53.50% (calculated using TTM income statement data). Kane Biotech earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Kane Biotech ROC % Historical Data

The historical data trend for Kane Biotech's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kane Biotech ROC % Chart

Kane Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -280.80 -171.88 -99.34 -53.54 -36.81

Kane Biotech Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -36.72 -46.56 -40.28 -58.36 -99.71

Kane Biotech ROC % Calculation

Kane Biotech's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=-3.357 * ( 1 - 0% )/( (7.009 + 11.233)/ 2 )
=-3.357/9.121
=-36.81 %

where

Kane Biotech's annualized Return on Capital (ROC %) for the quarter that ended in Sep. 2024 is calculated as:

ROC % (Q: Sep. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2024 ) + Invested Capital (Q: Sep. 2024 ))/ count )
=-2.444 * ( 1 - 0% )/( (2.761 + 2.141)/ 2 )
=-2.444/2.451
=-99.71 %

where

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kane Biotech  (TSXV:KNE) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Kane Biotech's WACC % is 6.51%. Kane Biotech's ROC % is -53.50% (calculated using TTM income statement data). Kane Biotech earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Kane Biotech ROC % Related Terms

Thank you for viewing the detailed overview of Kane Biotech's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Kane Biotech Business Description

Traded in Other Exchanges
Address
290-100 Innovation Drive, Winnipeg, MB, CAN, R3T 6G2
Kane Biotech Inc is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The company has a portfolio of biotechnologies, intellectual property and products developed by its own biofilm research expertise and acquired from research institutions. The Company has a separate operating segment for its Stem Animal Health subsidiary, which operates the animal health business. The firm is also engaged in the animal health business through its Stem Animal Health subsidiary.
Executives
Marc Edwards Director
Philip Renaud Director
Raymond David Eugene Dupuis Senior Officer
Richard J. Renaud 10% Security Holder
Georges Morin Director
Rashieda Gluck Director

Kane Biotech Headlines

No Headlines